XMax Inc. Wins Shareholder Approval for Significant Stock Dilution Through Private Placement and Shelf Offering

Special Meeting Results Confirm Dual Capital Raise Strategy

XMax Inc. held a special stockholder meeting on July 24, 2026, in which shareholders voted overwhelmingly to authorize two distinct equity issuances totaling more than 40% of the company's outstanding stock on a combined basis. The approval margins were substantial, with the private placement receiving approximately 98.9% support and the shelf offering receiving approximately 98.9% support among voting shareholders. The strength of these approval margins suggests that major stakeholders viewed the capital raises as necessary strategic measures, despite the significant dilutive impact on existing equity holders.

The disclosure does not reveal the specific dollar amounts the company intends to raise, the identities of anchor investors in the private placement, or the timeline for deploying these offerings. Investors may be watching for subsequent announcements that detail pricing, the use of proceeds, and expected closing dates for both transactions. The company's executives did not provide public commentary on the financing rationale in the filing itself.

Nasdaq Listing Rule Compliance Requirements Drive Shareholder Vote

Both equity issuances required shareholder approval under Nasdaq Listing Rule 5635(d) because they involved the sale of more than 20% of XMax's issued and outstanding common stock at prices lower than the rule's defined "Minimum Price" threshold. This dual requirement—exceeding the 20% volume cap and pricing below the minimum—triggered the mandatory shareholder vote. The rule exists to protect existing shareholders from excessive dilution and potential underpricing that could harm share value.

The private placement issuance represents a direct transaction with select investors outside the public markets, while the shelf issuance occurs under an effective Form S-3 registration statement (Registration Number 333-295406) filed previously with the Securities and Exchange Commission. The use of a Form S-3 indicates that XMax qualifies as a well-known seasoned issuer or has met other eligibility criteria allowing streamlined registration. The company did not disclose the specific minimum prices that triggered the rule compliance requirements or the discount percentages at which it plans to price the new shares.

Voting Breakdown Shows Minimal Shareholder Dissent

The voting tallies reveal remarkably consistent support across all three proposals submitted at the meeting. Proposal 1, which approved the private placement issuance, received 25,775,447 votes in favor, 279,140 votes against, and 52,402 abstentions. Proposal 2, addressing the shelf issuance, garnered 25,775,415 votes in favor, 279,146 votes against, and 52,428 abstentions. Proposal 3, which granted discretionary authority to the Chairman of the Board to adjourn the meeting if needed to solicit additional proxies, received 25,775,196 votes in favor, 279,478 votes against, and 52,315 abstentions.

The consistency of vote counts and the narrow range of opposing votes suggest that either a single large shareholder or a coordinated group controlled the vast majority of shares voted at the meeting. The low proportion of dissenting votes—less than 1.1% in each case—indicates that either major shareholders supported the capital raises or chose not to actively oppose them. The filing does not identify how many shares were represented by proxy, the identity of any dissenting shareholders, or whether management held controlling stakes that ensured passage.

Dilution Impact on Existing Shareholders

The approval of issuances totaling more than 40% of currently outstanding stock will materially reduce the ownership percentage held by existing shareholders unless they participate in the offerings. For investors holding a fixed number of shares, their pro-rata claim on XMax's earnings and assets will decline proportionally following the equity issuances. The immediate share price impact was not clear from available public information, as the filing does not include trading data or management guidance on expected stock performance.

The below-market pricing of both offerings compounds the dilutive effect by ensuring that new shares are issued at a discount to what Nasdaq considers fair value. This structure benefits incoming investors while further reducing the intrinsic value per share for existing holders. The company's decision to pursue capital at such terms may reflect constrained access to alternative financing, urgent liquidity needs, or strategic investor preferences that justified accepting unfavorable pricing in the company's assessment.

Form S-3 Registration Statement Availability

The shelf issuance operates under an effective Form S-3 registration statement on file with the Securities and Exchange Commission under Registration Number 333-295406. A Form S-3 registration allows a company to offer and sell securities on an expedited basis, typically useful for companies with established market presence and lower financing risk profiles. The existence of an effective S-3 means that XMax can launch the shelf offering quickly once shareholders approved the plan, without waiting for new registration statements to be drafted, reviewed, and declared effective.

The filing does not specify how much shelf capacity remains available under the existing registration or whether the company intends to file additional shelf registrations. Investors may review the SEC's EDGAR database to examine the original Form S-3 filing and any post-effective amendments for additional details about the offering terms, use of proceeds restrictions, and other conditions governing the shelf issuance. The company did not disclose the anticipated timing for launching or completing the shelf offering.

Chairman Authority to Adjourn Meeting

Proposal 3 granted discretionary authority to XMax's Chairman of the Board to adjourn the special meeting if he determined that additional proxy solicitations were necessary to secure approval for Proposals 1 and 2. The filing indicates that this contingency authority was approved by shareholders, but it does not state whether the Chairman ultimately exercised this authority or whether the meeting proceeded directly to completion on July 24, 2026. In practice, companies include such provisions to ensure they can secure adequate shareholder support even if initial voting results fall short of expectations, though the strong approval margins here suggest the adjournment authority was precautionary.

The high vote in favor of Proposal 3 (25,775,196 to 279,478 with 52,315 abstentions) demonstrates that shareholders were comfortable granting management this procedural flexibility. This authority typically expires once the underlying proposals receive shareholder approval or are withdrawn, and the company did not describe any scenario in which additional proxies would have been necessary given the overwhelming support for Proposals 1 and 2.

Corporate Domicile and Regulatory Status

XMax Inc. is a Nevada corporation with principal executive offices located at 6565 East Washington Boulevard, Commerce, California. The company holds Securities and Exchange Commission File Number 001-36259 and Internal Revenue Service Employer Identification Number 90-0746568. Its common stock is registered on the Nasdaq Stock Market under the ticker symbol XMAX. The filing does not identify XMax as an emerging growth company, meaning the company does not rely on reduced disclosure or compliance standards available to that category.

The Nevada incorporation provides XMax with certain corporate governance flexibility, though Nasdaq listing standards apply regardless of state of incorporation. The company's Nasdaq registration ensures that its shares trade on a major U.S. exchange, subject to Nasdaq's listing rules including Rule 5635(d) that required the shareholder vote documented in this disclosure. The filing does not provide information about XMax's business operations, financial condition, or competitive position.

Timing and Execution of Capital Raises

The special meeting occurred on July 24, 2026, and the company filed this disclosure with the Securities and Exchange Commission on July 28, 2026, within the required timeline for reporting material corporate events. The filing does not specify when the company expects to close or complete the private placement and shelf issuances following shareholder approval. Investors interested in the exact timing of capital deployment, any interim developments, or subsequent pricing announcements should monitor XMax's future regulatory filings and press releases.

The company did not disclose this figure in the filing regarding specific use-of-proceeds allocations, expected completion dates, or financial projections tied to the capital raises. Similarly, the announcement includes no management commentary justifying the capital raise strategy, competitive positioning, or strategic initiatives the new capital will fund. Stakeholders seeking more context about XMax's capital needs and strategic direction may need to review additional company disclosures, investor presentations, or earnings calls if the company has made such materials publicly available.

Implications for Existing Shareholders and Future Financing

The approval of these substantial equity issuances at below-market pricing signals that XMax required immediate capital access and was willing to accept significant ownership dilution and share price pressure to secure funding. The company's reliance on dilutive equity financing rather than debt or other capital sources may suggest either limited access to alternative financing or management's preference for preserving balance sheet flexibility by avoiding debt obligations. The filing provides no analysis of XMax's capital structure alternatives or financial condition relative to typical industry metrics.

Future shareholders and investors may be watching to see how XMax deploys the capital from these offerings and whether the company achieves operational improvements or growth that justify the near-term dilution. The substantial issuances also establish a precedent that could make future capital raises more challenging, as the market typically scrutinizes companies that frequently return for shareholder approval of dilutive offerings. The company did not disclose whether management anticipates additional capital raises in the near term or whether these issuances are intended to satisfy the company's financing needs for any specified forward period.